Sonelokimab for Moderate-to-Severe HS | Docwire News In two phase 3 trials, sonelokimab sustained efficacy through week 40 for patients with moderate-to-severe hidradenitis suppurativa.

According to data presented at #AAD2026 by Alexa Kimball (@BIDMCderm), #sonelokimab sustained efficacy through week 40, with durable pain and quality-of-life improvements, for patients with moderate-to-severe #HidradenitisSuppurativa. #Dermatology

www.docwirenews.com/post/sonelok...

Long Acting Anti–IL-4Rα Antibody for AD | Docwire News According to phase 3 data, long-term treatment with anti–IL-4Rα antibody MG-K10 showed durable efficacy among patients with moderate-to-severe atopic dermatitis.

According to a phase 3 trial presented at #AAD2026 by Dr Jianzhong Zhang of Peking University, long-term treatment with #MGK10 showed durable efficacy among for #AtopicDermatitis with an extended dosing interval. #Dermatology

www.docwirenews.com/post/long-ac...

Envudeucitinib for Psoriasis | Docwire News In two phase 3 studies, envudeucitinib improved skin clearance and signs and symptoms of psoriasis when compared with placebo or apremilast.

According to data presented at #AAD2026 by Dr Andrew Blauvert, #envudeucitinib improved signs and symptoms of #psoriasis compared with placebo or #apremilast.

www.docwirenews.com/post/envudeu...

Amlitelimab for Atopic Dermatitis | Docwire News According to results from three phase 3 clinical trials, amlitelimab monotherapy and with topical therapy improved atopic dermatitis symptoms regardless of dosing regimen.

According to data presented at #AAD2026 by Dr Eric Simpson of OHSU, #amlitelimab as monotherapy and in combination with topical therapy improved skin clearance for #AtopicDermatitis. #Dermatology

www.docwirenews.com/post/amlitel...

Azathioprine and Nonmelanoma Skin Cancer Risk | Docwire News According to a meta-analysis, there is an increased risk for squamous cell carcinomas among organ transplant recipients who have been treated with azathioprine.

A meta-analysis found there is an increased risk for #SquamousCellCarcinoma and #NonMelanomaSkinCancer among patients who have undergone organ transplants and have been treated with #azathioprine.
#Dermatology #Oncology #NMSC #SCC #BCC

www.docwirenews.com/post/associa...

Antibiotics and Immunotherapy in Melanoma | Docwire News Antibiotic use during immune checkpoint inhibitor therapy may be associated with improved overall survival among patients with advanced melanoma.

What is the impact of #antibiotic use on #immunotherapy for #melanoma? Check out the results of a retrospective study from Dr Vincent Ma (@uwmadison.bsky.social) at the link!
#Dermatology #Oncology #SkinCancer

www.docwirenews.com/post/impact-...

Stapokibart for Adolescents with Atopic Dermatitis | Docwire News Stapokibart showed significant efficacy and favorable safety among adolescent patients with moderate to severe atopic dermatitis when compared to placebo.

💊 According to phase 3 data, the anti–IL-4Rα monoclonal antibody #stapokibart showed significant efficacy and favorable safety among adolescent patients with moderate to severe #AtopicDermatitis when compared to placebo. Read the full summary at the link!

www.docwirenews.com/post/stapoki...

Biologics and Biosimilars in Dermatology | Docwire News Derm Immuno Today Editorial Board Member Steven Feldman, MD, comments on the current landscape of biologics and biosimilars in dermatology.

Commenting on #biosimilars in #dermatology, Dr Steve Feldman of Wake Forest says, "I don’t think we’ll be able to help more patients, and I think there will be some frustrating hurdles to navigate in this new landscape."

Read the full commentary below!